PARSIPPANY, N.J., Sep 08, 2021 (GLOBE NEWSWIRE via COMTEX) --
PARSIPPANY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.
today announced that it will present at the H.C. Wainwright 23
Annual Global Investment Conference at 7:00 AM ET on Monday, September 13, 2021. Pre-recorded audio of the virtual event can be accessed by visiting the "Events" page of the company's website at investor.pacira.com
. A replay of the webcast will also be available for two weeks following the event.
Pacira BioSciences, Inc. /zigman2/quotes/202929053/composite PCRX -1.43% is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local analgesic, EXPAREL(R) (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam(R), a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera�(R) system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com .
Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.firstname.lastname@example.org
Is there a problem with this press release? Contact the source provider Comtex at email@example.com. You can also contact MarketWatch Customer Service via our Customer Center.
(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.